CNCE / Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2022 Results - Earnings Call Transcript

Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. The CVR is based on two sales mil more_horizontal

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in t more_horizontal

The company is changing hands in a deal worth at least $576 million. more_horizontal

Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold c more_horizontal

Concert (CNCE) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is more_horizontal

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Sen more_horizontal

If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the seve more_horizontal

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will report its financial results for the second quarter of 2022, on Thursday, Au more_horizontal